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Purpose of the study
HIV-associated lipoatrophy may affect up to 35% of
patients who have received antiretroviral therapy for more
than one year, and results in depression, social isolation,
and career barriers. Interventions, such as dermal fillers,
are licensed for restoration of facial fat loss in persons liv-
ing with HIV. As only few insurance plans, if any, provide
reimbursement for such procedures, patients must con-
sider the pros and cons of such interventions, weighing
these against the other costs of daily life. The primary goal
of this study is to provide reliable estimates of the costs of
treating HIV-associated lipoatrophy, specifically facial
lipoatrophy.
Methods
Costs are estimated from published studies reporting
administration patterns of dermal fillers, publicly availa-
ble list prices, and physician service fees for similar subcu-
taneous injections of the face. Fourteen studies were
identified that reported experience with five dermal fillers
used to treat HIV-associated facial lipoatrophy: poly-L-lac-
tic acid, calcium hydroxylapatite, polyalkylimide gel,
hyaluronic acid, and silicone oil. Two products, poly-L-
lactic acid and calcium hydroxylapatite, are semi-perma-
nent injectable fillers with effect lasting up to 18–24
months and are approved by the FDA. Hyaluronic acid is
a temporary filler and the effect would usually last up to a
year. Polyalkylimide gel and silicone oil are permanent
fillers. Data were collected from these 14 studies on the
dosage, treatment schedule, and amount of product
administered for each product. Cost of dermal filler for a
single site such as malar, is estimated as the product of (i)
the number of visits per course, (ii) units of product used
per visit, and (iii) the price per unit of filler.
Summary of results
Typical courses involve four physician visits on average
but could vary from one to 13. The unit price for each der-
mal filler ranges from $123 for 1 mL of poly-L-lactic acid
to $1,250 for 1 mL of silicone oil. The cost of a course of
dermal-filler treatment at a single facial site ranges from
$3,690 to $16,544, which typically is not covered by the
payers. Physician fees for similar outpatient procedures
reimbursed by insurers are approximately $500, and may
vary according to location, specialty, and market condi-
tions.
Conclusion
Treatment of HIV-associated lipoatrophy may represent a
considerable out-of-pocket expense for many patients and
will influence their treatment decisions and care path-
ways.
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